Gilde Healthcare leads $24 million financing round of respiratory care provider Vapotherm - Gilde Healthcare

Gilde Healthcare leads $24 million financing round of respiratory care provider Vapotherm

April 7, 2014

EXETER, New Hampshire – Vapotherm, Inc. announced a $24MM financing round led by Gilde Healthcare. Adage Capital Management joined as new co-investor. The round was completed by existing investors Morgenthaler Ventures, Kaiser Permanente, 3×5 Special Opportunity Fund, Integral Capital Partners, QuestMark Partners and Cross Creek Capital.

Geoff Pardo, Partner of Gilde Healthcare joins as new member of the Board of Directors:

“Vapotherm’s unique respiratory solution has proven to generate superior patient outcomes and lower the cost of care for providers. We look forward to grow the company internationally and improve healthcare for patients world-wide.”

Vapotherm develops, manufactures and markets advanced respiratory care devices. The company sells innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 600,000 patients have been treated with Vapotherm’s proprietary high flow therapy. For more information, visit www.vtherm.com.

 

About Gilde Healthcare (www.gildehealthcare.com)

Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts) is a transatlantic growth capital investor focused on private healthcare companies. It has over €450 million ($600 million) under management and is actively looking to lead new investments in therapeutics, diagnostics, medical devices and healthcare services. For a list of Gilde’s portfolio companies please visit our new website at www.gildehealthcare.com.

Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling...
July 9, 2025

Gilde Healthcare’s private equity fund combines Artinis and NIRx into a world-leading neuroimaging group

Gilde Healthcare today announces the combined private equity investments in Artinis Medical Systems (Netherlands) and NIRx Medical Technologies (Germany/United States), both pioneers in functional Near-Infrared Spectroscopy (fNIRS) solutions. This dual transaction brings together two highly...
July 8, 2025

Gilde Healthcare company SpliceBio secures $135 Million financing to advance SB-007 in Stargardt disease and expand pipeline

Financing co-led by new investors EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund, as well as Gilde Healthcare and other existing investors  Proceeds will support clinical development of lead program SB-007...
June 11, 2025